Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aneuploidy selects for the acquisition of driver genes in breast cancer.

Nature·2026
Same author

WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.

NPJ breast cancer·2026
Same author

Unintended consequences of legacy oversight in digital medicine.

Nature medicine·2026
Same author

Paired CRISPR screens identify mitochondrial metabolism and UBE2H as aneuploid-specific dependencies in human cancer cell lines.

bioRxiv : the preprint server for biology·2026
Same author

Autostaining Immune Multiplex Immunohistochemistry Panels and Imaging Analysis.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Mapping intratumor heterogeneity across layers for advancing immunotherapy.

Cell·2026

Related Experiment Video

Updated: Jul 8, 2025

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.8K

Engrailed-1 Promotes Pancreatic Cancer Metastasis.

Jihao Xu1,2, Jae-Seok Roe3,4, EunJung Lee1,4,5

  • 1Department of Microbiology and Molecular Genetics, University of California Davis, Davis, CA, 95616, USA.

Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|December 19, 2023
PubMed
Summary
This summary is machine-generated.

Engrailed-1 (EN1), a transcription factor, drives aggressive pancreatic cancer. Targeting EN1 and its pathways may offer new therapeutic strategies for pancreatic ductal adenocarcinoma (PDA).

Keywords:
ERK signalingEngrailed-1apoptosiscancer progressioncancer therapeuticsdevelopmental transcription factorepigenetic reprogrammingmetastasispancreatic ductal adenocarcinoma

More Related Videos

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

1.4K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.6K

Related Experiment Videos

Last Updated: Jul 8, 2025

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
06:20

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer

Published on: October 4, 2022

2.8K
Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
03:42

Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models

Published on: September 27, 2024

1.4K
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:17

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

10.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Engrailed-1 (EN1) is a crucial transcription factor for neuronal survival.
  • EN1 expression is linked to aggressive triple-negative breast cancer.
  • Aberrant EN1 expression is observed in a subset of pancreatic ductal adenocarcinoma (PDA) patients.

Purpose of the Study:

  • To investigate the role of EN1 in pancreatic ductal adenocarcinoma (PDA).
  • To determine the impact of EN1 on PDA progression and patient outcomes.

Main Methods:

  • Analysis of EN1 expression in PDA patient samples.
  • In vitro and in vivo gain- and loss-of-function experiments.
  • Chromatin immunoprecipitation to identify EN1 target genes.

Main Results:

  • EN1 is aberrantly expressed in PDA patients with poor prognosis.
  • EN1 represses target genes by binding to enhancers and promoters.
  • EN1 promotes PDA cell transformation and metastasis.
  • EN1 activation of MAPK pathways and mesenchymal properties are implicated.

Conclusions:

  • EN1 plays a significant role in promoting PDA.
  • Targeting EN1 and its downstream pathways presents a potential therapeutic strategy for aggressive PDA.